<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00616135</url>
  </required_header>
  <id_info>
    <org_study_id>RESTORE-2</org_study_id>
    <nct_id>NCT00616135</nct_id>
  </id_info>
  <brief_title>Study of Autologous Fat Enhanced w/ Regenerative Cells Transplanted to Reconstruct Breast Deformities After Lumpectomy</brief_title>
  <acronym>RESTORE-2</acronym>
  <official_title>A Clinical Evaluation Of Adipose Derived Regenerative Cells In The Treatment Of Patients With BrEast Deformities Post Segmental Breast ResecTion (Lumpectomy) With Or Without Radiation ThErapy. A Phase IV Post Market Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cytori Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cytori Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A post-marketing study evaluating the transplantation of autologous fat augmented with
      Adipose Derived Regenerative Cells (ADRCs), in patients with functional and cosmetic breast
      deformities post segmental mastectomy or quadrantectomy (lumpectomy).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2008</start_date>
  <completion_date type="Actual">November 2010</completion_date>
  <primary_completion_date type="Actual">November 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Patient and physician satisfaction with functional and cosmetic results. Improvement in overall breast deformity measured at 12 months compared to baseline.</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in breast volume and shape at 6 and 12 Months compared to baseline. Improvement in skin pigmentation abnormalities at 6 and 12 months compared to Baseline. Improvement in overall breast deformity at 6 Months compared to Baseline.</measure>
    <time_frame>6 months and 12 months</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">71</enrollment>
  <condition>Breast Neoplasms</condition>
  <condition>Carcinoma, Ductal, Breast</condition>
  <condition>Mammaplasty</condition>
  <condition>Mastectomy, Segmental, Lumpectomy, Breast Reconstruction,</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>ADRC-Enhanced Autologous Fat Transplant</intervention_name>
    <description>Autologous fat harvested from the patient is enhanced with ADRCs derived from a portion of the harvested fat and transplanted into the breast(s) that have a volume deficit post lumpectomy. This is a single arm study with no control. All patients receive cell therapy.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Females with a history of T2N0M0 breast carcinoma (tumor ≤3 cm in largest dimension)

          -  Surgical or endoscopic segmental mastectomy or quadrantectomy (lumpectomy)

          -  Clean surgical margins

          -  No prosthesis in breast(s) to undergo treatment

          -  Ability to undergo lipoaspiration

          -  Last treatment for breast cancer ≥ 12 months prior to enrollment with absence of
             recurrence (patients on anti-estrogen adjuvant therapy are NOT excluded)

          -  No evidence of recurrence of cancer based on mammogram or breast exam prior to
             enrollment

          -  Objective signs of mild breast damage post Breast Conservation Therapy

          -  Type I Cosmetic Sequelae Classification

          -  A minimum of 1 cm of soft tissue (e.g. breast or fat) is available between the skin
             and chest wall at the recipient site

          -  A minimum of two-thirds of the breast is remaining post Breast Conservation Therapy

          -  No continuous adhesion of skin to bone &gt;3 cm in diameter

          -  The volume and shape of the defect(s) must be conducive to correction during a single
             treatment session (maximum defect volume ≤150 mL in breast(s) to undergo treatment)

        Exclusion Criteria:

          -  History of autoimmune disorder (e.g., Systemic Lupus Erythematosus [SLE])

          -  History of connective, metabolic or atrophic skin disease

          -  History of keloid scarring

          -  Chronic use (&gt;7 consecutive days) of anticoagulants (such as aspirin) or NSAIDs within
             15 days prior to enrollment

          -  Life expectancy ≤ 2 years

          -  Recurrence or active malignancy requiring radiation or surgical treatment ≤12 months
             prior to enrollment

          -  Presence of any other known malignancy

          -  Body Mass Index (BMI) &gt;30

          -  Plan to undergo weight reduction surgery or foresee any significant weight changes
             during the study (defined as changes in BMI &gt;5 compared to baseline

          -  Presence of contraindications to MRI
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Jules Bordet Institute of Cancer</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Università degli Studi di Firenze</name>
      <address>
        <city>Florence</city>
        <zip>50134</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Gregorio Marañon</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Valenciano Oncologia</name>
      <address>
        <city>Valencia</city>
        <zip>46009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glasgow Royal Infirmary</name>
      <address>
        <city>Glasgow</city>
        <state>Scotland</state>
        <zip>G4 0SF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>France</country>
  </removed_countries>
  <verification_date>May 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 5, 2008</study_first_submitted>
  <study_first_submitted_qc>February 5, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 15, 2008</study_first_posted>
  <last_update_submitted>May 13, 2011</last_update_submitted>
  <last_update_submitted_qc>May 13, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 17, 2011</last_update_posted>
  <responsible_party>
    <name_title>Sean Gemmill, MS, RAC; Clinical Research Manager</name_title>
    <organization>Cytori Therapeutics</organization>
  </responsible_party>
  <keyword>Breast</keyword>
  <keyword>Stem Cell</keyword>
  <keyword>Adipose Derived Stem Cells</keyword>
  <keyword>Adipose Derived Regenerative Cells</keyword>
  <keyword>ADRC</keyword>
  <keyword>Reconstructive Breast Surgery</keyword>
  <keyword>Breast Reconstruction</keyword>
  <keyword>Cancer</keyword>
  <keyword>Carcinoma</keyword>
  <keyword>Autologous fat transplantation</keyword>
  <keyword>Autologous fat</keyword>
  <keyword>Cosmetic breast deformities</keyword>
  <keyword>Functional breast deformity</keyword>
  <keyword>Lumpectomy</keyword>
  <keyword>Segmental mastectomy</keyword>
  <keyword>Quadrantectomy</keyword>
  <keyword>breast conservation therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Congenital Abnormalities</mesh_term>
    <mesh_term>Carcinoma, Ductal</mesh_term>
    <mesh_term>Carcinoma, Ductal, Breast</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

